Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas

[1]  I. Blümcke,et al.  Spontaneous In Vitro Transformation of Adult Neural Precursors into Stem‐Like Cancer Cells , 2009, Brain pathology.

[2]  A. Ashworth,et al.  A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines , 2009, Breast Cancer Research and Treatment.

[3]  A. Ashworth,et al.  The genomic profile of HER2‐amplified breast cancers: the influence of ER status , 2008, The Journal of pathology.

[4]  Denis Lacombe,et al.  Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[6]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[7]  Hanna Göransson,et al.  Screening for copy‐number alterations and loss of heterozygosity in chronic lymphocytic leukemia—A comparative study of four differently designed, high resolution microarray platforms , 2008, Genes, chromosomes & cancer.

[8]  A. Ashworth,et al.  Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast , 2008, The Journal of pathology.

[9]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[10]  Anne Vincent-Salomon,et al.  ESR1 gene amplification in breast cancer: a common phenomenon? , 2008, Nature Genetics.

[11]  R. McLendon,et al.  Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. , 2008, Neuro-oncology.

[12]  T. MacDonald,et al.  Protein Expression of Platelet-Derived Growth Factor Receptor Correlates with Malignant Histology and PTEN with Survival in Childhood Gliomas , 2008, Clinical Cancer Research.

[13]  Alan Mackay,et al.  Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines , 2008, Laboratory Investigation.

[14]  O. Lingjaerde,et al.  ESR1 gene amplification in breast cancer: a common phenomenon? , 2008, Nature Genetics.

[15]  C. Hawkins,et al.  Tyrosine kinase expression in pediatric high grade astrocytoma , 2008, Journal of Neuro-Oncology.

[16]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[17]  H. Newton.  Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors. , 2007, Current opinion in investigational drugs.

[18]  Å. Borg,et al.  Screening for Copy Number Alterations and Loss of Heterozygosity in Chronic Lymphocytic Leukemia - A Comparative Study of Four Differently Designed, High Resolution Microarray Platforms. , 2007 .

[19]  Webster K. Cavenee,et al.  Erratum: The 2007 WHO classification of tumours of the central nervous system (Acta Neuropathol (2007) vol. 114 (97-109)) , 2007 .

[20]  M. J. van den Bent,et al.  Molecular targeted therapies and chemotherapy in malignant gliomas , 2007, Current opinion in oncology.

[21]  R. Reis,et al.  Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series , 2007, Journal of Clinical Pathology.

[22]  Johan Staaf,et al.  BIOINFORMATICS ORIGINAL PAPER doi:10.1093/bioinformatics/btm359 Data and text mining , 2022 .

[23]  J. Reis-Filho,et al.  Molecular Alterations of KIT Oncogene in Gliomas , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[24]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[25]  Andreas von Deimling,et al.  Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. , 2007, Neuro-oncology.

[26]  B. Coe,et al.  Resolving the resolution of array CGH. , 2007, Genomics.

[27]  E. Holland,et al.  Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment. , 2007, Neurosurgery clinics of North America.

[28]  Alan Mackay,et al.  Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation , 2007, Laboratory Investigation.

[29]  K. Wong,et al.  Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival , 2007, Journal of Neuro-Oncology.

[30]  R. McLendon,et al.  Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas , 2007, Journal of Neuro-Oncology.

[31]  A. Paetau,et al.  Amplification of KIT, PDGFRA, VEGFR2, and EGFR in Gliomas , 2006, Molecular Cancer Research.

[32]  Howard A. Fine,et al.  Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.

[33]  C. Heldin,et al.  Characterization of an imatinib-sensitive subset of high-grade human glioma cultures , 2006, Oncogene.

[34]  S. Vandenberg,et al.  PDGFRα-Positive B Cells Are Neural Stem Cells in the Adult SVZ that Form Glioma-like Growths in Response to Increased PDGF Signaling , 2006, Neuron.

[35]  C. Dominici,et al.  Increased sensitivity to the platelet‐derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF‐BB‐mediated signaling and STI571‐induced Akt inactivation , 2006, Journal of cellular physiology.

[36]  A. Buschauer,et al.  Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity , 2006, Journal of Cancer Research and Clinical Oncology.

[37]  A. Ashworth,et al.  Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization , 2006, Laboratory Investigation.

[38]  E. Holland,et al.  Platelet-derived growth factor (PDGF) and glial tumorigenesis. , 2006, Cancer letters.

[39]  David N Louis,et al.  Molecular pathology of malignant gliomas. , 2006, Annual review of pathology.

[40]  A. Longatto-Filho,et al.  Molecular Characterization of PDGFR-α/PDGF-A and c-KIT/SCF in Gliosarcomas , 2005, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[41]  Allan H Friedman,et al.  Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Alonso,et al.  Real-Time Quantitative PCR Analysis of Regions Involved in Gene Amplification Reveals Gene Overdose in Low-Grade Astrocytic Gliomas , 2005, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[43]  S. Levy,et al.  Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. Joensuu,et al.  Amplification of genes encoding KIT, PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme , 2005, The Journal of pathology.

[45]  Albino Martins,et al.  Overexpression of platelet-derived growth factor receptor α in breast cancer is associated with tumour progression , 2005, Breast Cancer Research.

[46]  M. Alonso,et al.  Real-time quantitative PCR analysis of gene dosages reveals gene amplification in low-grade oligodendrogliomas. , 2005, American journal of clinical pathology.

[47]  K. Franssila,et al.  KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. Reis,et al.  Mutation analysis of B-RAF gene in human gliomas , 2005, Acta Neuropathologica.

[49]  Christian Hartmann,et al.  Pdgfr‐α in 1p/19q LOH oligodendrogliomas , 2004 .

[50]  A. Ullrich,et al.  The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.

[51]  L. Puricelli,et al.  EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomas , 2004, Journal of surgical oncology.

[52]  Christian Hartmann,et al.  Pdgfr-alpha in 1p/19q LOH oligodendrogliomas. , 2004, International Journal of Cancer.

[53]  Tobias Sjöblom,et al.  PDGF receptors as cancer drug targets. , 2003, Cancer cell.

[54]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[55]  Alex Matter,et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.

[56]  M. Israel,et al.  Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. , 2002, Cancer research.

[57]  M. Nistér,et al.  Prognostic value of platelet derived growth factor α receptor expression in grade 2 astrocytomas and oligoastrocytomas , 2002, Journal of neurology, neurosurgery, and psychiatry.

[58]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[59]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[60]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[61]  C. James,et al.  Amplification of the Platelet‐Derived Growth Factor Receptor‐A (PDGFRA) Gene Occurs in Oligodendrogliomas with Grade IV Anaplastic Features , 2000, Journal of neuropathology and experimental neurology.

[62]  Kelvin H. Lee,et al.  Genomic analysis. , 2000, Current opinion in biotechnology.

[63]  M. Nistér,et al.  Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. , 1998, Cancer research.

[64]  R. Carroll,et al.  Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. , 1998, Neurosurgery.

[65]  R. Carroll,et al.  Expression of platelet-derived growth factor transcripts in medulloblastomas and ependymomas. , 1996, Pediatric neurosurgery.

[66]  D. Louis,et al.  Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. , 1996, Cancer research.

[67]  C. Heldin,et al.  Platelet‐derived growth factor in human glioma , 1995, Glia.

[68]  A. Guha,et al.  Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop , 1995, International journal of cancer.

[69]  K. Plate,et al.  Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[70]  E. Oldfield,et al.  Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. , 1992, Cancer research.

[71]  C. Heldin,et al.  Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.

[72]  T. Yoshimoto,et al.  Amplification of alpha-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin. , 1992, Oncogene.

[73]  C. Heldin,et al.  Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. , 1991, The Journal of biological chemistry.

[74]  T. Mapstone.  Expression of platelet-derived growth factor and transforming growth factor and their correlation with cellular morphology in glial tumors. , 1991, Journal of neurosurgery.

[75]  P. Black,et al.  Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. , 1990, The Journal of clinical investigation.

[76]  C. Heldin,et al.  Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[77]  T. Libermann,et al.  Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. , 1988, Cancer research.

[78]  W. Richardson,et al.  A role for platelet-derived growth factor in normal gliogenesis in the central nervous system , 1988, Cell.